This is an interesting series of events here, and if the failure rate is high, why are the hips being “phased” out, in other words are they still being sold until the end of this year as the article states? …
Personally from doing this blog it doesn’t appear to me that we have a shortage in the development area, but where the issues lie is in standards and bringing some of this to a better collaborative effort. You do NOT…
This company has been in the news for a couple years now and if you haven’t followed this company as far as development, politics, the FDA and more, it has a little bit of everything. Even with biotech drugs getting…
This proves interesting as Allergan back in October last year filed a law suit for the “off label” warning to be removed, in other words the “black box” warning. Allegan is also facing competition in this area that sells the…
We are back to the same 3 companies again, Johnson and Johnson, Boston Scientific and Abbott, same questions over “patents” and more legal expenses to pass along to consumers in the price of a stent. If these 3 could settle…
Many individuals that have had hip replacements that are metal to metal and perhaps not a combination of metal and/or other material needing to be replaced. The article mentions the Mayo Clinic has reduced their number used by 80%. With…
Myriad may somewhat be a familiar name and if you don’t know who the company is think about the HER breast cancer gene test, that’s the company and now they have come out with a genetics based test to help…
This is a smart move to create additional algorithmic formulas to analyze labs along with medications being taken. For a simple example I am estimating based on a particular lab result, certain drugs would not be advisable treatment and on…
This is an interesting medical device from Uroplasty called the “Urgent PC” and requires a few treatments and they do a demonstration on the video below. Patients with pacemakers or implanted defibrillators though are out of the picture for obvious…
There may be some additional software issues here creating problems. The FDA is studying reports to find out why, it is the software or perhaps an easier user interface needed, or maybe a combination of both.
One more time we…
